GO:0005457 GDP-fucose transmembrane transporter activity

GDP-fucose transmembrane transporter activity (GO:0005457) is the molecular function that enables transfer of GDP-fucose, a nucleotide-sugar composed of fucose in glycosidic linkage with guanosine diphosphate, from one side of a membrane to the other. In eukaryotic cells this activity is essential because the enzymes that attach fucose to proteins and lipids (fucosyltransferases) are located inside the lumen of the endoplasmic reticulum and Golgi apparatus, while GDP-fucose is synthesized in the cytosol. Without a dedicated transporter, the substrate cannot reach the fucosylation machinery and the entire fucosylation program stalls. The function was first defined genetically in humans through complementation cloning of leukocyte adhesion deficiency type II (LAD II), also classified as congenital disorder of glycosylation type IIc (CDG-IIc), where the defective gene was identified as a GDP-fucose transporter. In parallel, the same gene was reported as the defect underlying LAD II and named a putative GDP-fucose transporter. A functional ortholog was subsequently cloned in Drosophila melanogaster, confirming evolutionary conservation of the activity. More recently, a second endoplasmic reticulum import pathway was shown to function redundantly in O-fucosylation of Notch in Drosophila, indicating that cells can use more than one route to deliver GDP-fucose to the lumen. For researchers, GO:0005457 matters because it sits at the intersection of glycobiology, immunology and oncology. Loss of function produces a defined human disease with immune and neurological phenotypes, while increased fucosylation downstream of this transport step sustains oncogenic signaling in intrahepatic cholangiocarcinoma and correlates with patient prognosis. The term therefore provides a precise functional annotation for interpreting CRISPR screens, glycomics and disease variant data.

In practical terms, GO:0005457 is the activity of a membrane-embedded protein that binds GDP-fucose on one side of a lipid bilayer and releases it on the other side, without chemically modifying the substrate. The official definition states that it enables the transfer of GDP-fucose from one side of a membrane to the other, where GDP-fucose is a substance composed of fucose in glycosidic linkage with guanosine diphosphate. This is a transport function, not an enzymatic reaction: the transporter does not cleave GDP from fucose. The activity is required to supply luminal fucosyltransferases with their donor substrate, and its loss in humans causes a glycosylation disorder with leukocyte adhesion deficiency.

GO:0005457 is important because it controls the supply of the only known donor substrate for all protein and lipid fucosylation in the secretory pathway. When this transport activity is lost, fucosylated glycans such as sialyl Lewis X are not made, which impairs selectin-mediated leukocyte rolling and causes the immunodeficiency of LAD II / CDG-IIc. When the activity is elevated or rewired, increased fucosylation can sustain oncogenic signaling pathways and is associated with worse prognosis in intrahepatic cholangiocarcinoma. Because the function is conserved from Drosophila to humans, it can be dissected genetically and biochemically, making it a tractable target for both mechanistic glycobiology and therapeutic hypothesis testing.

The genes below are directly implicated in GDP-fucose transmembrane transporter activity or in the fucosylation pathway it supplies, based on the verified literature.

Regulation of GDP-fucose transmembrane transporter activity is best understood through its genetic requirement and pathway redundancy. In humans, the activity is encoded by SLC35C1, and loss-of-function variants cause LAD II / CDG-IIc, demonstrating that the transporter is non-redundant for selectin ligand synthesis in leukocytes. In Drosophila, however, two pathways for importing GDP-fucose into the endoplasmic reticulum lumen function redundantly in O-fucosylation of Notch, indicating that cells can compensate when one route is impaired. This redundancy is a key regulatory feature: it buffers luminal GDP-fucose supply and can mask loss-of-function phenotypes depending on cell type and developmental stage. In cancer, aberrant fucosylation sustained by this transport activity is linked to activation of NOTCH and EGFR/NF-kB signaling, suggesting that oncogenic signaling and glycosylation are reciprocally regulated.

Complementation cloning identified CDG-IIc, a new type of congenital disorder of glycosylation, as a GDP-fucose transporter deficiency. In parallel, the gene defective in leukocyte adhesion deficiency II was reported to encode a putative GDP-fucose transporter. Patients present with severe immunodeficiency due to loss of fucosylated selectin ligands, which impairs leukocyte rolling and extravasation. This is the canonical human disease linked to GO:0005457.

Aberrant fucosylation sustains the NOTCH and EGFR/NF-kB pathways and has prognostic value in human intrahepatic cholangiocarcinoma. This connects the transport activity and its downstream fucosylation products to tumor signaling and clinical outcome.

In Drosophila, redundant GDP-fucose import pathways into the endoplasmic reticulum lumen are required for O-fucosylation of Notch, a key developmental signaling receptor. Perturbation of this transport step can therefore affect Notch-dependent developmental processes.

Because GO:0005457 supplies the donor substrate for fucosylation, loss of activity can be measured by loss of fucosylated glycans using lectins and mass spectrometry. These assays directly read out the functional consequence of transporter perturbation in cells and patient samples.

Direct measurement of GDP-fucose transport across membranes can be performed using vesicle-based uptake assays, which test the biochemical activity defined by GO:0005457. Such assays are useful for validating patient variants and engineered mutations.

Complementation cloning was the approach that identified CDG-IIc as a GDP-fucose transporter deficiency. Rescue experiments in Drosophila and human cells can test whether candidate transporters restore fucosylation.

In cancer models, RNA-seq and pathway reporters can measure NOTCH and EGFR/NF-kB signaling downstream of altered fucosylation. These readouts connect transporter activity to oncogenic programs and prognosis.

Researchers studying GDP-fucose transmembrane transporter activity-related genes often need to determine whether a candidate gene is causally involved in fucosylation, immune cell adhesion or cancer signaling, or whether it is merely a bystander in a larger glycosylation network. Establishing causality requires precise genetic models that isolate the transporter step from downstream fucosyltransferases and signaling pathways.

GO:0005457 GDP-fucose transmembrane transporter activity is a precise molecular function that links cytosolic nucleotide-sugar metabolism to luminal protein fucosylation. Its founding human gene SLC35C1 is defective in LAD II / CDG-IIc, and its Drosophila ortholog Gfr provides a tractable genetic model, while redundant endoplasmic reticulum import pathways add layers of regulation. In cancer, aberrant fucosylation downstream of this activity sustains NOTCH and EGFR/NF-kB signaling and carries prognostic value. Together, these findings make the transporter an important node for glycobiology, immunology and oncology research. Because the function is genetically defined and conserved, CRISPR knockout, point-mutation, knock-in and overexpression models are well suited to test causality and to identify modifiers of fucosylation-dependent phenotypes. Such models, combined with glycomics and signaling readouts, will continue to clarify how GDP-fucose transport shapes development, immunity and cancer.